Speaker: Frauke Zipp, Professor of Neurology, Chair of Neurology, University Medicine Mainz, Germany
What key insights will you be sharing in your session and why is this important?
Frauke Zipp: I am Frauke Zipp from Mainz University from Germany, and I will be talking at ECTRIMS about CAR-T cell therapy in autoimmune diseases. This concept, originally developed for cancer, is now in the focus in the area of autoimmune diseases. The genetically modified T cells recognise and deplete. For example, CD19 expressing B cells also within tissue so within the brain. Therefore, the hope is to tackle smouldering pathology in the brain and spinal cord in people with multiple sclerosis, which has to be certainly shown in all the trials currently running. And I will talk about trials in this area as well. In my talk, I will give an overview on development, advantage, problems and evidence as well as planned strategies on chimeric antigen receptor, and that is CAR-T cell therapy in neurological autoimmune diseases, including multiple sclerosis. And I have the pleasure to give this lecture and would be happy if you have time to listen.
